predicted prognosis accurately in patients from France [58], Canada [45, 46], and those with low grade tumours, but less accurate in patients from UK [59], Ireland [60], Malaysia [61], South Korea [44], Taiwan [62], those with lympho-vascular invasion [45, 61], BRCA1-mutation carriers [63], and those with high grade tumours [44, 58, 59, 61, 62]. This evidence concerns the gene BRCA1 and neoplasm.